Biologic

In this Healio video exclusive, Michael V. Chiorean, MD, explains that physicians can safely and “with confidence” switch patients with inflammatory bowel disease from an originator biologic to a biosimilar at any point during treatment.

Patients with hidradenitis suppurativa are hesitant to use adalimumab — which is recommended as a first-line treatment for the skin condition — as well as other biologics, according to a study.

Abrocitinib downregulated genes associated with inflammation, epidermal hyperplasia, and T helper 2 and T helper 22 responses in the skin of patients with moderate to severe atopic dermatitis, according to a study published in Allergy.

The introduction of biologics as a therapeutic option for Crohn’s disease had “only a slight impact” on eventual surgery occurrence, although it may delay the first intestinal resection compared with conventional therapy, data showed.

Careers in allergy and asthma can take physicians into private, corporate or academic work as well as into professional organizations. Michael S. Blaiss, MD, a new member of Healio’s Allergy/Asthma Peer Perspective Board, has done it all.

WAILEA, Hawaii — Although it is still unknown which orthobiologics should be used to treat athletes with knee injuries, various biologic tools may be used to help identify such uses in the future, according to a presenter here.

Patients with rheumatoid arthritis are increasingly receiving non-TNF inhibitors, which additionally demonstrate higher retention rates, compared with other biologics, according to data published in Nature Scientific Reports.

Switching between biosimilars and reference products did not increase the risk for death or serious adverse events, according to a meta-analysis conducted by FDA investigators.

At 1-year follow-up, various cell-based injections were not superior to a corticosteroid injection for pain and radiological outcomes in patients with knee osteoarthritis, according to results published in Nature Medicine.

ANAHEIM, Calif. — “There are a lot of interesting trends,” John J. Oppenheimer, MD, FACAAI, clinical professor at UMDNJ Rutgers, told Healio at the American College of Allergy, Asthma & Immunology 2023 Annual Scientific Meeting.